Protocol for enhancing CRISPR-Cas9 genome editing using histone deacetylase inhibition and engineered virus-like particle delivery.

Mahbod Djamshidi, Ryota Tanida, Katayoun Heshmatzad, Hokan Krowicki, Alexander Hill, Yang Yang, Karl Riabowol

Abstract read

In one paragraph

Article in STAR protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mahbod DjamshidiRobson DNA Sciences Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada; Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada; Arthur JE Childs Comprehensive Cancer Institute, University of Calgary, Calgary, AB, Canada; Departments of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

Ryota TanidaRobson DNA Sciences Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada; Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada; Arthur JE Childs Comprehensive Cancer Institute, University of Calgary, Calgary, AB, Canada; Departments of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

Katayoun HeshmatzadRobson DNA Sciences Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada; Arthur JE Childs Comprehensive Cancer Institute, University of Calgary, Calgary, AB, Canada; Departments of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

Hokan KrowickiRobson DNA Sciences Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada; Arthur JE Childs Comprehensive Cancer Institute, University of Calgary, Calgary, AB, Canada; Departments of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

Alexander HillArthur JE Childs Comprehensive Cancer Institute, University of Calgary, Calgary, AB, Canada.

Yang YangRobson DNA Sciences Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada; Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada; Arthur JE Childs Comprehensive Cancer Institute, University of Calgary, Calgary, AB, Canada; Departments of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

Karl RiabowolRobson DNA Sciences Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada; Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada; Arthur JE Childs Comprehensive Cancer Institute, University of Calgary, Calgary, AB, Canada; Departments of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada; Departments of Oncology, University of Calgary, Calgary, AB, Canada; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. Electronic address: karl@ucalgary.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a 10-fold faster, accurate, and more efficient (FAME)-CRISPR-Cas9 gene editing workflow utilizing histone deacetylase inhibitor (HDACi)-mediated chromatin relaxation and engineered virus-like particle (eVLP) delivery of Cas9. We describe steps for optimizing HDACi concentration, euchromatinization timing, and Cas9 delivery/expression to improve CRISPR-Cas9 editing efficiency and efficacy. This protocol can eliminate the need for single-cell cloning and reduce experimental timelines up to 10-fold while minimizing HDACi-mediated toxicity. For complete details on the use and execution of this protocol, please refer to Djamshidi et al.

Indexed as

CRISPR-Cas SystemsGene EditingHistone Deacetylase InhibitorsVirionHumansHistone Deacetylase InhibitorsCell BiologyCRISPRGeneticsMolecular Biology

Identifiers

PMID42012982

DOI10.1016/j.xpro.2026.104493

PMCPMC13122305

What Socratic holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.